Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up Women only

Topical estrogen cream to improve recovery for transgender men after hysterectomy

Official title: Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy

Run by Women and Infants Hospital of Rhode Island · NCT06969326 · Data updated 2026-11-12

This study tests if using a special estrogen cream after surgery can help transgender men recover better and feel more comfortable after a hysterectomy.

More Hysterectomy trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment48 (estimated)
SponsorWomen and Infants Hospital of Rhode Island
Academic / other
Locations1 site (Providence, Rhode Island)
StatusRecruiting
StartedMay 1, 2025
Main results expectedSeptember 1, 2026
Study endsDecember 1, 2026
Registry record updatedMay 13, 2025
Trial IDNCT06969326 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are transgender men aged 18 or older who have been on testosterone for at least six months and are planning to undergo a gender-affirming hysterectomy.

Probably not a fit

Patients who are under 18, have not been on testosterone for the required duration, or have known allergies to topical estrogen may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of applying a single dose of topical estrogen cream at the end of a hysterectomy to enhance the postoperative experience for transgender men. The aim is to reduce postoperative bleeding and alleviate symptoms of dysphoria, which can be exacerbated by vaginal bleeding following surgery. By comparing outcomes between those receiving the estrogen treatment and those who do not, the study seeks to determine if this intervention should be integrated into standard postoperative care for this population. The findings could provide valuable insights into improving recovery experiences for transgender men undergoing gender-affirming surgeries.

Why it matters

Potential benefit: If successful, this intervention could significantly improve the postoperative experience and reduce dysphoria for transgender men undergoing hysterectomy.

How similar studies have gone: While the use of topical estrogen in this specific context is novel, similar approaches in managing postoperative care have shown promise in other studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Gender diverse/transgender men
2. Age 18 or older
3. Have been on testosterone for at least 6 months with plan to undergo gender-affirming hysterectomy and are willing to be randomized to the use of topical estrogen postoperatively.
4. Have stable physical and mental health
5. No contraindications to estrogen therapy
6. Must be proficient in English or Spanish
7. Must have access to a device to receive text messages for study follow up
8. Must agree to allow their medical data to be used for research purposes

Exclusion Criteria:

1. Under age 18
2. Have not been on testosterone for at least 6 months prior to planned hysterectomy
3. Known allergy to topical estrogen

Where it's running

  • Women & Infants Hospital
    Providence, Rhode Island, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.